{"meta":{"query_hash":"41558b7674d1","filters":{"venue":"Pharmaceutical Patent Analyst"},"cohort_total":8,"direct_labels_cover":0,"predictions_cover":8,"exported":8,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/41558b7674d1","api":"https://metacan.xera.ac/api/v1/cohort?venue=Pharmaceutical+Patent+Analyst"},"results":[{"id":"W1997836420","doi":"10.4155/ppa.12.62","title":"The patent-regulatory Regime in Canada","year":2012,"lang":"en","type":"article","venue":"Pharmaceutical Patent Analyst","topic":"Intellectual Property and Patents","field":"Business, Management and Accounting","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Women's and Gender Studies et Recherches Féministes","funders":"","keywords":"Notice; Political science; Economic Justice; Food and drug administration; Orphan drug; Business; Library science; Law; Medicine; Biology; Pharmacology; Computer science; Bioinformatics","score_opus":0.253747303083136,"score_gpt":0.26827586577306856,"score_spread":0.014528562689932578,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1997836420","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96568316,0.0022881401,0.00003738557,0.0027562408,0.0019343568,0.0003965348,0.0000030574029,0.00006849965,0.02683263],"genre_scores_gemma":[0.9945024,0.000067048895,0.0000034189782,0.0038393245,0.0008611006,0.00002189586,0.000018132503,0.000024832481,0.0006618154],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9979389,0.000049856273,0.00041869798,0.00022809434,0.0004923748,0.00087211287],"domain_scores_gemma":[0.9993648,0.00010960985,0.000109127126,0.000251,0.00009769377,0.00006777321],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00074679166,0.00022370389,0.00021931727,0.00011520157,0.00031900703,0.0001295049,0.00037781202,0.000048394497,0.0008072641],"category_scores_gemma":[0.00012291195,0.00014144645,0.0001023202,0.00056056975,0.00008031107,0.0005792948,0.00018570102,0.00034485984,0.00091892],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037958048,0.00026882274,0.92839104,0.00014152775,0.00020546577,0.000053525928,0.00008713263,0.0002739562,0.00080666406,0.0069414135,0.040882625,0.021568252],"study_design_scores_gemma":[0.0016953321,0.000009181433,0.16157496,0.000082919956,0.0003024145,0.000007643132,0.00071475486,0.07006121,0.0012012845,0.00058435235,0.76285124,0.00091470906],"about_ca_topic_score_codex":0.47979814,"about_ca_topic_score_gemma":0.3429113,"teacher_disagreement_score":0.7668161,"about_ca_system_score_codex":0.00027512896,"about_ca_system_score_gemma":0.00009769224,"threshold_uncertainty_score":0.999859},"labels":[],"label_agreement":null},{"id":"W2064679735","doi":"10.4155/ppa.14.39","title":"Inhibitors of voltage-gated Sodium Channel Na <sub>v</sub> 1.7: Patent Applications Since 2010","year":2014,"lang":"en","type":"review","venue":"Pharmaceutical Patent Analyst","topic":"Ion channel regulation and function","field":"Biochemistry, Genetics and Molecular Biology","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Xenon Pharmaceuticals (Canada)","funders":"","keywords":"Sodium channel; Chemistry; Sodium; Nanotechnology; Materials science; Organic chemistry","score_opus":0.09180525462218428,"score_gpt":0.3306597990516639,"score_spread":0.23885454442947965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064679735","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00025685417,0.96300197,0.033056885,0.000108014625,0.0014734259,0.0016330534,0.00018141537,0.0000709405,0.00021741888],"genre_scores_gemma":[0.03806979,0.9560991,0.000023118811,0.00012970215,0.0014325065,0.0002539577,0.003562832,0.00009186568,0.00033715507],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9970282,0.00023418455,0.0010973759,0.00079645007,0.00039215753,0.00045166368],"domain_scores_gemma":[0.9980978,0.000042388932,0.0006266346,0.00055824185,0.00035065823,0.00032428475],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046251604,0.0005608789,0.0011188973,0.00027212882,0.00014026389,0.00003342157,0.00033762064,0.0006173852,0.000033505425],"category_scores_gemma":[0.00006219094,0.0004773468,0.0009258112,0.00052900665,0.00021047158,0.0000073577894,0.00019993752,0.00040391978,0.00018276219],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0001513087,0.0007941754,0.000035401015,0.01111385,0.0014789668,0.0000064979176,0.000020216201,0.0003110356,0.054834455,0.00020863216,0.0073371073,0.9237084],"study_design_scores_gemma":[0.0005047941,0.00009849109,0.000004148549,0.0006037889,0.001252457,0.000013240182,0.000008978575,0.0030116674,0.037250366,0.000015871596,0.9566811,0.0005551395],"about_ca_topic_score_codex":0.000007985177,"about_ca_topic_score_gemma":0.0000032343005,"teacher_disagreement_score":0.9493439,"about_ca_system_score_codex":0.00006674723,"about_ca_system_score_gemma":0.00013572056,"threshold_uncertainty_score":0.99976784},"labels":[],"label_agreement":null},{"id":"W2092351901","doi":"10.4155/ppa.12.45","title":"Differentiating Stem Cell Patents","year":2012,"lang":"en","type":"review","venue":"Pharmaceutical Patent Analyst","topic":"Pluripotent Stem Cells Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Systems, Applications & Products in Data Processing (Canada)","funders":"","keywords":"Stem cell; Embryonic stem cell; Induced pluripotent stem cell; Patentability; Regenerative medicine; Biology; Cell biology; Adult stem cell; Patent law; Genetics; Computer science; Intellectual property","score_opus":0.232632293917567,"score_gpt":0.393937842891255,"score_spread":0.16130554897368798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2092351901","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003766028,0.9965968,0.00021319532,0.000009882539,0.00038736852,0.00073930284,0.00010784543,0.000032599757,0.0015363932],"genre_scores_gemma":[0.011712774,0.9824869,0.000033938755,0.000043053064,0.00069338444,0.00012711881,0.0013372249,0.00013575431,0.003429819],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9957183,0.00067611877,0.00089020666,0.0009212615,0.00064082927,0.0011532891],"domain_scores_gemma":[0.99809897,0.00005432198,0.0003513184,0.00071653,0.00010834204,0.0006705274],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00056234654,0.0007270012,0.0013169274,0.000210498,0.00015654345,0.000088096705,0.0007982979,0.0005408908,0.00028811413],"category_scores_gemma":[0.000013480508,0.0005728888,0.0011466171,0.0003365977,0.00010131181,0.0000069131843,0.0008333586,0.0007263109,0.0010453785],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000028999704,0.00049324235,0.00044639502,0.015812619,0.0010247278,0.00003497308,0.000009700689,0.0000026790724,0.0031382097,0.000005768737,0.0007310596,0.9782716],"study_design_scores_gemma":[0.00039152498,0.000053095166,0.000008344603,0.00068255985,0.0024238573,0.000019764184,0.000008341807,0.00011066129,0.00193386,0.0000010700239,0.9936969,0.00067000685],"about_ca_topic_score_codex":0.0000070413766,"about_ca_topic_score_gemma":0.0000018305984,"teacher_disagreement_score":0.9929659,"about_ca_system_score_codex":0.00009978495,"about_ca_system_score_gemma":0.00011918407,"threshold_uncertainty_score":0.99973243},"labels":[],"label_agreement":null},{"id":"W2165246524","doi":"10.4155/ppa.14.31","title":"Advances and Strategies in NADPH Oxidase Inhibitors and Activators Patents","year":2014,"lang":"en","type":"review","venue":"Pharmaceutical Patent Analyst","topic":"Neutrophil, Myeloperoxidase and Oxidative Mechanisms","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hyperion Technologies (Canada)","funders":"","keywords":"NADPH oxidase; NOx; Enzyme; Reactive oxygen species; Biochemistry; Chemistry; Pharmacology; Biology; Computational biology","score_opus":0.0789722978028615,"score_gpt":0.3555411628673972,"score_spread":0.2765688650645357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2165246524","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0060555544,0.9924882,0.000047046055,0.000042020416,0.00039937685,0.0006094309,0.00005356963,0.000054574197,0.00025024294],"genre_scores_gemma":[0.05096109,0.94841,0.000017853294,0.000083736566,0.00007046029,0.00009095717,0.00019983738,0.000050921575,0.00011516063],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99669325,0.00080509274,0.0008566541,0.00089569576,0.0000894127,0.0006599035],"domain_scores_gemma":[0.99895406,0.00029428402,0.0003066858,0.0002574976,0.0000460443,0.00014145733],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043353322,0.0007304958,0.002052035,0.00047295206,0.00016828747,0.00008098751,0.00024369115,0.0004973116,0.00018030882],"category_scores_gemma":[0.00004905965,0.0005354604,0.00025915244,0.00038711677,0.0004310914,0.00030988108,0.00027357825,0.0010239512,0.00015547544],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00008609764,0.00019020018,0.00023799653,0.0080304425,0.00053988857,0.000092402865,0.00006967718,6.819604e-7,0.0044912524,0.001191122,0.000085938416,0.9849843],"study_design_scores_gemma":[0.0013021071,0.000142324,0.000029007322,0.0033067488,0.0011237256,0.00007493995,0.0001614937,0.000007958007,0.0020069473,0.0003298228,0.9907472,0.00076773216],"about_ca_topic_score_codex":0.000048370515,"about_ca_topic_score_gemma":0.000024380493,"teacher_disagreement_score":0.99066126,"about_ca_system_score_codex":0.00007567712,"about_ca_system_score_gemma":0.000080367696,"threshold_uncertainty_score":0.99970967},"labels":[],"label_agreement":null},{"id":"W2274414307","doi":"10.4155/ppa-2016-0001","title":"Biologics and Biosimilars: a Legal Perspective From Canada","year":2016,"lang":"en","type":"editorial","venue":"Pharmaceutical Patent Analyst","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Medicine; Library science; Christian ministry; Family medicine; Political science; Internal medicine; Law; Computer science","score_opus":0.04711475273903797,"score_gpt":0.33904405110552555,"score_spread":0.29192929836648757,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2274414307","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000881643,0.040970936,0.00019767534,0.013085975,0.93009675,0.000542705,0.011055575,0.00015604607,0.0030126814],"genre_scores_gemma":[0.10531021,0.01818711,0.00067669677,0.008167501,0.85369927,0.00010939792,0.0030363444,0.00025587744,0.010557589],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9962872,0.00069518754,0.00065225497,0.0012495719,0.0002391949,0.00087658357],"domain_scores_gemma":[0.99637944,0.0022885962,0.0002499975,0.00043252777,0.0004328184,0.0002166032],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00050346705,0.0007027547,0.0011794325,0.0001382148,0.00022811633,0.000069501366,0.0005325312,0.0016997046,0.0022369046],"category_scores_gemma":[0.0013182143,0.00044944236,0.00029582015,0.00021385649,0.00080427894,0.000071941504,0.00040795346,0.001789767,0.00008766559],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033099085,0.00009118563,0.00030572276,0.000026588226,0.0017729134,0.0000859321,0.0000130126855,6.493018e-8,0.009929046,0.00019435906,0.98533696,0.0019132342],"study_design_scores_gemma":[0.0014489084,0.00011635779,0.00010695179,0.00010223559,0.0013657442,0.000005154901,0.00009738085,0.000015368525,0.007030377,0.0005392072,0.9884824,0.0006898918],"about_ca_topic_score_codex":0.15277022,"about_ca_topic_score_gemma":0.07297825,"teacher_disagreement_score":0.10442857,"about_ca_system_score_codex":0.00052690954,"about_ca_system_score_gemma":0.00075273734,"threshold_uncertainty_score":0.99979573},"labels":[],"label_agreement":null},{"id":"W2771876169","doi":"10.4155/ppa-2017-0038","title":"Canada's Supreme Court Abolishes ‘promise of the patent’","year":2017,"lang":"en","type":"article","venue":"Pharmaceutical Patent Analyst","topic":"Intellectual Property and Patents","field":"Business, Management and Accounting","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"World Wildlife Fund Canada","funders":"","keywords":"Supreme court; Doctrine; Law; Subject matter; Statutory law; Certainty; Supreme Court Decisions; Political science; Patent law; Law and economics; Economics; Intellectual property; Philosophy","score_opus":0.27371656525676563,"score_gpt":0.28500588786895853,"score_spread":0.011289322612192898,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2771876169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9185005,0.00031465877,0.000050016853,0.010711845,0.0023913,0.0006688064,0.00004098194,0.0000631693,0.06725872],"genre_scores_gemma":[0.9953524,0.00003151812,0.000006125749,0.0027138991,0.0005989519,0.00001065866,0.000014361912,0.00002422126,0.0012478611],"study_design_codex":"observational","study_design_gemma":"not_applicable","domain_scores_codex":[0.9981715,0.000030005998,0.00042230336,0.00030875552,0.00061743776,0.00044996053],"domain_scores_gemma":[0.9985982,0.00003752951,0.00035764024,0.000646714,0.00031510353,0.000044806402],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00037854622,0.00023869319,0.00032395337,0.00006723242,0.0007846263,0.00030950914,0.0011861023,0.00006550985,0.0012199588],"category_scores_gemma":[0.00039494963,0.00014814897,0.00021418449,0.00017638304,0.0002455472,0.00050594646,0.00052745803,0.00028954755,0.00014618975],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0008469041,0.00069471356,0.80045134,0.00093001453,0.000875852,0.000103041595,0.00010976398,0.0004495817,0.0119404625,0.00557687,0.16506067,0.012960816],"study_design_scores_gemma":[0.0034170416,0.000021810967,0.28298634,0.0003198652,0.0013624907,0.000006530183,0.00016773805,0.09621131,0.019251823,0.0015054689,0.59364116,0.0011083971],"about_ca_topic_score_codex":0.40264204,"about_ca_topic_score_gemma":0.10999139,"teacher_disagreement_score":0.517465,"about_ca_system_score_codex":0.000054011038,"about_ca_system_score_gemma":0.00012120833,"threshold_uncertainty_score":0.99969304},"labels":[],"label_agreement":null},{"id":"W2911140943","doi":"10.4155/ppa-2018-0024","title":"Discussions on the New Molecular Formula and New Molecular Entity Definitions of Pharmaceutical Innovation","year":2018,"lang":"en","type":"article","venue":"Pharmaceutical Patent Analyst","topic":"Pharmaceutical Economics and Policy","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services","funders":"","keywords":"MEDLINE; Medicine; Library science; Computer science; Political science","score_opus":0.27535559192031356,"score_gpt":0.35251569796290894,"score_spread":0.07716010604259538,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2911140943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.7989794,0.0020850971,0.041897245,0.08300163,0.0007009267,0.0010266638,0.00044177048,0.00010556726,0.071761705],"genre_scores_gemma":[0.9896103,0.000640491,0.00037418888,0.0088803135,0.00023982183,0.000015315774,0.00003466005,0.00003444378,0.00017044984],"study_design_codex":"theoretical_or_conceptual","study_design_gemma":"theoretical_or_conceptual","domain_scores_codex":[0.99777466,0.00006209431,0.0009970035,0.0005235644,0.000114451745,0.0005282304],"domain_scores_gemma":[0.99854964,0.000162837,0.00029170644,0.00041168137,0.00008302351,0.0005011325],"candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00064532354,0.00028733065,0.00047359554,0.0003902283,0.00021039165,0.00010349621,0.0003593334,0.00012314453,0.002122444],"category_scores_gemma":[0.0003375623,0.00023539287,0.00022482658,0.0009297541,0.00036948008,0.00018342167,0.00020186299,0.00043568472,0.0005894832],"study_design_candidate":"theoretical_or_conceptual","study_design_consensus":"theoretical_or_conceptual","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000069164154,0.0001772069,0.0015428313,0.00002058369,0.00022566506,0.0000046879827,0.00009304212,0.000036625755,0.0073486343,0.98411506,0.00394977,0.0024167344],"study_design_scores_gemma":[0.003399339,0.00028190826,0.0023961049,0.000067300134,0.00034332802,0.000013641356,0.00005308085,0.050480448,0.094889194,0.6603082,0.1868683,0.0008992137],"about_ca_topic_score_codex":0.0001319652,"about_ca_topic_score_gemma":0.000009394551,"teacher_disagreement_score":0.3238069,"about_ca_system_score_codex":0.00008063318,"about_ca_system_score_gemma":0.00006945327,"threshold_uncertainty_score":0.9987897},"labels":[],"label_agreement":null},{"id":"W4220679694","doi":"10.4155/ppa-2021-0027","title":"Baicalein: Promising Therapeutic Applications With Special Reference to Published Patents","year":2022,"lang":"en","type":"review","venue":"Pharmaceutical Patent Analyst","topic":"Flavonoids in Medical Research","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Baicalein; Scutellaria baicalensis; Pharmacology; Medicine; Traditional medicine; Traditional Chinese medicine; Pathology","score_opus":0.4173883201346984,"score_gpt":0.48348445466439033,"score_spread":0.06609613452969193,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4220679694","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000019279465,0.96173203,0.0013875389,0.001426388,0.00022615402,0.0073591033,0.00009904828,0.00021553868,0.027534911],"genre_scores_gemma":[0.00022627768,0.9894003,0.0005247239,0.0009163432,0.0017456872,0.0033406096,0.0009730315,0.00018020753,0.0026927877],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99268985,0.0006219017,0.0012352352,0.0015039656,0.002757653,0.0011913996],"domain_scores_gemma":[0.99570787,0.0006539874,0.0002548235,0.0011983268,0.00026225625,0.0019227125],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0013946891,0.00074582075,0.0025032235,0.0007956655,0.00034069375,0.00019997587,0.0010621155,0.0003369592,0.019135859],"category_scores_gemma":[0.0005849588,0.0005011953,0.0006011888,0.0030065158,0.00033934542,0.000113620474,0.0006406445,0.003547446,0.0011244421],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023846439,0.00070979854,0.0000737536,0.007839023,0.0009920744,0.00023959258,0.000022347505,0.0000012945428,0.000015811369,0.0006790446,0.001751331,0.9874375],"study_design_scores_gemma":[0.0008760778,0.00034889692,0.000019886136,0.0022826097,0.003971813,0.00004361714,0.000027232436,0.00011208794,0.00000759857,0.000101187085,0.9916778,0.00053114473],"about_ca_topic_score_codex":0.000016208938,"about_ca_topic_score_gemma":0.0000048012034,"teacher_disagreement_score":0.9899265,"about_ca_system_score_codex":0.0010415412,"about_ca_system_score_gemma":0.0011426271,"threshold_uncertainty_score":0.99974394},"labels":[],"label_agreement":null}]}